EligibleTrials

Trop2-targeted immunoPET Imaging of Solid Tumors

Recruiting · NCT06851663 · Interventional (participants receive a specific treatment) · Lead sponsor: RenJi Hospital

View the official record on ClinicalTrials.gov →
Prostate CancerLung Cancer

Interventions studied

[18F]F-RESCA-RT4[18F]F-RESCA-T4[68Ga]Ga-NOTA-RT4[68Ga]Ga-NOTA-T4

What this trial is about

This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.

Who can take part

Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2, Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.